Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Cern scientists restart hunt for answers to mysteries of universe
    • Eurozone inflation hits record 8.6% in June
    • Biden administration floats new oil leasing plan in Gulf of Mexico
    • How worried should we be about new Covid variants?
    • US Supreme Court’s blockbuster term reverberates through America
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • US government bonds rally after factory data heighten recession fears
    • Google closes data loophole amid privacy fears over abortion ruling
    • Central banks look to China’s renminbi to diversify foreign currency reserves
    • Biden administration floats new oil leasing plan in Gulf of Mexico
    • US Supreme Court’s blockbuster term reverberates through America
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Klarna valuation crashes to $6.5bn from $46bn
    • Ryanair chief warns fares will rise for 5 years because flying is ‘too cheap’
    • EY wins share of BNP audit amid break-up planning
    • Putin orders transfer of Sakhalin-2 gas project to Russian entity
    • Covid could not sink cruise lines — but they now face an iceberg of debt
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Klarna valuation crashes to $6.5bn from $46bn
    • US government bonds rally after factory data heighten recession fears
    • Live news updates: Crypto broker Voyager Digital suspends trading and withdrawals
    • A soft landing is becoming a distant dream
    • The looming risks in private equity returns
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The end of the frictionless life
    • A soft landing is becoming a distant dream
    • Time to change my subscription model
    • We may not agree with the Taliban but we should help Afghanistan
    • The looming risks in private equity returns
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • What’s a good (and bad) way to leave your job?
    • How can I move from being a specialist police detective to financial services?
    • If you want to be more likeable, try showing more stress
    • ‘Exactly how much virtue do you really want to signal?’
    • JSR’s Eric Johnson: ‘I encourage people to tell me exactly how they think’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Life on the idyllic Swedish island where WW3 could start
    • Serhii Plokhy: Putin’s imperialist narrative ‘is being crushed’
    • The end of the frictionless life
    • Have we had enough of the nanny employer?
    • Time to change my subscription model
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

GlaxoSmithKline PLC

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 24 June, 2022
    Covid-19 vaccines
    Sanofi-GSK Covid vaccine found effective against Omicron

    Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

  • Monday, 13 June, 2022
    Sanofi SA
    Sanofi and GSK report ‘positive’ results from Covid booster

    ‘Next-generation’ jab delivers strong immune response against variants

  • Friday, 10 June, 2022
    Pharmaceuticals sector
    GSK hopes for boost from respiratory virus jab

    Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline

  • Wednesday, 1 June, 2022
    Pharmaceuticals sector
    Pfizer to exit GSK consumer health joint venture after London listing

    US pharma group to sell down stake in Haleon business after July IPO

  • Wednesday, 1 June, 2022
    Lex
    GSK: consumer demerger is the right prescription for UK drugs giant Premium content

    Spinning off the business will make more bolt-on deals possible

  • Tuesday, 31 May, 2022
    GSK to buy US biotech group Affinivax in $3bn deal

    UK drugmaker to pay $2.1bn upfront plus another potential $1.2bn as it boosts its vaccines business

  • Friday, 27 May, 2022
    Pharmaceuticals sector
    ViiV ‘actively negotiating’ voluntary licence for HIV prevention drug

    GSK-controlled company in talks with UN-backed body on generic manufacture of highly effective PrEP injection

  • Wednesday, 27 April, 2022
    GSK beats forecasts on back of Covid and shingles treatments

    UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’

  • Wednesday, 20 April, 2022
    GSK workers vote to strike over below inflation pay rise

    Several hundred staff set stage for first walkout in drugmaker’s history

  • Wednesday, 13 April, 2022
    GSK to buy Sierra Oncology for £1.5bn to boost cancer drug pipeline

    Sierra’s bone marrow cancer treatment had positive clinical trial results in January

  • Friday, 11 March, 2022
    City InsiderBryce Elder
    Critics call foul over GlaxoSmithKline’s vaccine push

    Plus, speculation surrounds Ted Baker, and Russian connections give Jefferies an ESG headache

  • Friday, 4 March, 2022
    Moncef Slaoui
    Trump vaccine chief returns $3.9mn to GSK over sexual harassment claims

    Drugmaker recoups cash from Moncef Slaoui for non-compliance with company policies

  • Wednesday, 2 March, 2022
    Cat Rutter Pooley
    GSK and Haleon will need time to thrive apart

    As split nears completion, investors turn attention to what comes next

  • Monday, 28 February, 2022
    GSK expects to spin off Haleon consumer business in July

    UK drugmaker ‘extremely confident’ despite market uncertainty over Ukraine

  • Wednesday, 23 February, 2022
    Covid-19 vaccines
    Sanofi and GSK to seek approval for delayed Covid vaccine

    Drugmakers to apply for protein-based shot to be used as primary and booster jabs

  • Wednesday, 9 February, 2022
    GSK pledges to step up growth as it prepares for consumer unit spin-off

    Quarterly profits at UK drugmaker beat expectations and sales of Covid treatment hit £958mn

  • Wednesday, 9 February, 2022
    City Bulletin
    GSK hails ‘step change in growth’ ahead of split Premium content

    Plus, mutual insurers LV and Royal London end talks and BP’s best defence against a windfall tax

  • Thursday, 27 January, 2022
    GSK kicks off trials of pioneering ‘bioelectronic’ disease treatment

    The first patient has been given an implant to control rheumatoid arthritis by modifying nerve signals to the spleen

  • Thursday, 20 January, 2022
    Unilever PLC
    Terry Smith launches new attack on Unilever management

    Top shareholder urges executives to improve business rather than chase big acquisitions

  • Wednesday, 19 January, 2022
    Unilever PLC
    Unilever rules out increasing £50bn bid for GSK unit after backlash

    Top-10 investor Flossbach ‘would strongly oppose’ a deal for consumer business

  • Wednesday, 19 January, 2022
    GSK loses top scientist to anti-ageing start-up

    Departure of Hal Barron comes as pharma group faces pressure to revive drug pipeline

  • Tuesday, 18 January, 2022
    Personal & Household Goods
    Unilever’s pursuit of GSK business could trigger credit downgrade, warns Fitch

    Rating agency says group risks losing A status that it is determined to retain

  • Tuesday, 18 January, 2022
    LexUnilever PLC
    Unilever/GSK: slicing the salami should attract buyers Premium content

    Consumer goods group has gems it could sell piecemeal

  • Tuesday, 18 January, 2022
    Helen Thomas
    The challenge to GSK from Unilever’s blockbuster consumer bid

    UK pharma company may still prefer to list its consumer health unit but the bar for success is now higher

  • Tuesday, 18 January, 2022
    Due Diligence
    The New York PR maven entangled in Leon Black’s legal battle Premium content

    Plus, Unilever places the bid no one asked for and British pensioners unwittingly fund a controversial spyware group

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In